AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial

[Reuters] – AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. The trial . . . → Read More: AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial Similar posts: Market Update on McDonalds Corporation (NYSE:MCD) – McDonald’s helps workers get food stamps Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review Chevron goes to trial in New York over $18 billion Ecuador award – Chevron Corporation (NYSE:CVX)